Fasching PA, Loibl S, Hu C. et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the Gepar-Quinto Study. J Clin Oncol 2018; DOI: 10.1200/JCO.2017.77.2285.
Download Bibliographical Data
We do not assume any responsibility for the contents of the web pages of other providers.